Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models.

ABSTRACT:

Background

Particular breast cancer subtypes pose a clinical challenge due to limited targeted therapeutic options and/or poor responses to the existing targeted therapies. While cell lines provide useful pre-clinical models, patient-derived xenografts (PDX) and organoids (PDO) provide significant advantages, including maintenance of genetic and phenotypic heterogeneity, 3D architecture and for PDX, tumor-stroma interactions. In this study, we applied an integrated multi-omic approach across panels of breast cancer PDXs and PDOs in order to identify candidate therapeutic targets, with a major focus on specific FGFRs.

Methods

MS-based phosphoproteomics, RNAseq, WES and Western blotting were used to characterize aberrantly activated protein kinases and effects of specific FGFR

SUBMITTER: Chew NJ 

PROVIDER: S-EPMC8336364 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature